Effects of mndpdp and icrf-187 on doxorubicin-induced cardiotoxicity and anticancer activity

Translational Oncology

Volumn 5, Issue 4, 2012, Pages 252-259

  Kurz, Tino ^a   Grant, Derek ^b   Andersson, Rolf G G ^a   Towart, Robertson ^c   De Cesare, Michelandrea ^d   Karlsson, Jan Olof G ^a,e  

^a LINKÖPING UNIVERSITY   (Sweden)

^b GE HEALTHCARE   (Norway)

^c Fondazione IRCCS Istituto Nazionale Tumori di Milano ^*

^d NATIONAL CANCER INSTITUTE   (Italy)

^e PledPharma AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; MANGAFODIPIR; RAZOXANE;

ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARDIOTOXICITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; FENTON REACTION; HEART LEFT ATRIUM; HEART MUSCLE CONTRACTILE FORCE; HEART MUSCLE CONTRACTILITY; HEART PROTECTION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; TUMOR XENOGRAFT;

EID: 84865494178     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.11304     Document Type: Article

References (44)

1. Shan K, Lincoff AM, and Young J (1996). Anthracycline-induced cardiotoxicity. Ann Intern Med 125, 47-58.
2. Simunek T, Sterba M, Popelova O, Adamcova M, Hrdina R, and Gersl V (2009). Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 61, 154-171.
3. Lenihan DJ (2006). Diagnosis and management of heart failure in cancer patients. In Cancer and the Heart. MS Ewer and E Yeh (Eds). BC Decker, Hamilton, Ontario, Canada. pp. 129-138.
4. Thomas X, Le QH, and Fiere D (2002). Anthracycline-related toxicity requiring cardiac transplantation in long-term disease-free survivors with acute promyelocytic leukemia. Ann Hematol 81, 504-507.
5. Wallace KB (1997). Free-radical-mediated chemical cardiomyopathies. In Free Radical Toxicology. KB Wallace (Ed). Taylor & Francis Ltd, London, UK. pp. 205-221.
6. Xu X, Persson HL, and Richardson DR (2005). Molecular pharmacology of the interaction of anthracyclines with iron. Mol Pharmacol 68, 261-271.
7. Doroshow JH, Locker GY, and Myers CE (1980). Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest 65, 128-135.
8. Chen Y, Saari JT, and Kang YJ (1994). Weak antioxidant defences make the heart a target for damage in copper-deficient rats. Free Radical Biol Med 17, 529-536.
9. Shattock MJ and Haddock PS (1995). Oxidant stress and the heart: modulation of ion transport mechanisms during ischaemia and reperfusion. In Immunopharmacology of Free Radical Species. D Black and PG Winyard (Eds). Academic Press Ltd, London, UK. pp. 65-72.
10. Singal PK, Deally CMR, and Weinberg LE (1987). Subcellular effects of adriamycine in heart: a concise review. J Mol Cell Cardiol 19, 817-828.
11. Kliment CR, Suliman HB, Tobolewski JM, Reynolds CM, Day BJ, Zhu X, McTiernan CF, McGaffin KR, Piantadosi CA, and Oury TD (2009). Extra-cellular superoxide dismutase regulates cardiac function and fibrosis. J Mol Cell Cardiol 47, 730-742.
12. Speyer JL, Green MD, Kramer E, Rey M, Sanger J, Ward C, Dubin N, Ferrans V, Stecy P, Zeleniuch-Jacquotte A, et al. (1988). Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 91, 745-752.
13. Asplund A, Grant D, and Karlsson JOG (1994). Mangafodipir (MnDPDP)-and MnCl2-induced endothelium-dependent relaxation in bovine mesenteric arteries. J Pharmacol Exp Ther 271, 609-614.
14. Brurok H, Ardenkjaer-Larsen JH, Hansson G, Skarra S, Berg K, Karlsson JO, Laursen I, and Jynge P (1999). Manganese dipyridoxyl diphosphate: MRI contrast agent with antioxidative and cardioprotective properties? Biochem Biophys Res Commun 254, 768-772.
15. Karlsson JOG (2004). Antioxidant activity of mangafodipir is not a new finding. J Hepatol 40, 872-873.
16. Karlsson JO, Brurok H, Towart R, and Jynge P (2006). The magnetic resonance imaging contrast agent mangafodipir exerts antitumor activity via a previously described superoxide dismutase mimetic activity. Cancer Res 66, 598.
17. Karlsson JOG, Brurok H, Eriksen M, Towart R, Toft KG, Moen O, Engebretsen B, Jynge P, and bibum H (2001). Cardioprotective effects of the MR contrast agent MnDPDP and its metabolite MnPLED upon reperfusion of the ischemic porcine myocardium. Acta Radiol 42, 540-547.
18. Smith HJ (2001). Contrast-enhanced MR imaging in the diagnosis and preservation of cardiac viability. Acta Radiol 42, 539.
19. Doroshow JH (2006). Redox modulation of chemotherapy-induced tumor cell killing and normal tissue toxicity. J Natl Cancer Inst 98, 223-225.
20. Laurent A, Nicco C, Chéreau C, Goulvestre C, Alexandre J, Alves A, Levy E, Goldwasser F, Panis Y, Soubrane O, et al. (2005). Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res 65, 948-956.
21. Alexandre J, Nicco C, Chéreau C, Laurent A, Weill B, Goldwasser F, and Batteux F (2006). Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir. J Natl Cancer Inst 98, 236-244.
22. Karlsson JO, Adolfsson K, Thelin B, Jynge P, Andersson RG, and Falkmer UG (2012). First clinical experience with the magnetic resonance imaging contrast agent and superoxide dismutase mimetic mangafodipir as an adjunct in cancer chemotherapy-a translational study. Transl Oncol 5, 32-38.
23. Baird SK, Kurz T, and Brunk UT (2006). Metallothionein protects against oxidative stress-induced lysosomal destabilization. Biochem J 15, 275-283.
24. Ahlner J, Axelsson KL, Ljusegren ME, Norlander B, and Andersson RG (1987). Retention and subsequent liberation of glyceryl trinitrate in organ baths influences the relaxation of bovine mesenteric arteries contracted by various agents. Pharmacol Toxicol 61, 316-319.
25. Rocklage SM, Cacheris WP, Quay SC, Hahn FE, and Raymond KN (1989). Manganese(II) N,N'-dipyridoxylethylenediamine-N,N'-diacetate 5, 5-bis(phosphate). Synthesis and characterization of a paramagnetic chelate for magnetic resonance imaging enhancement. Inorg Chem 28, 477-485.
26. Scully RE and Lipshultz SE (2007). Anthracycline cardiotoxicity in long-term survivors of childhood cancer. Cardiovasc Toxicol 7, 122-128.
27. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, and Muggia FM (1979). Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91, 710-717.
28. Swain SM, Whaley FS, and Ewer MS (2003). Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97, 2869-2879.
29. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, Friedman DL, Marina N, Hobbie W, Kadan-Lottick NS, et al. (2006). Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 355, 1572-1582.
30. Hensley ML, Schuchter LM, Lindley C, Meropol NJ, Cohen GI, Broder G, Gradishar WJ, Green DM, Langdon RJ Jr, Mitchell RB, et al. (1999). American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 17, 3333-3355.
31. Yeh ETH, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, Durand J-B, Gibbs H, Zafarmand AA, and Ewer MS (2004). Cardiovascular complications of cancer therapy diagnosis, pathogenesis, and management. Circulation 109, 3122-3131.
32. Hellmann K (2000). Dexrazoxane and the ASCO guidelines for the use of chemotherapy and radiotherapy protectants: a critique. J Clin Oncol 18, 2004-2006.
33. Swain SM and Vici P (2004). The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. J Cancer Res Clin Oncol 130, 1-7.
34. Hofland KF, Thougaard AV, Sehested M, and Jensen PB (2005). Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin. Clin Cancer Res 15, 3915-3924.
35. Van Dalen EC, Caron HN, Dickinson HO, and Kremer LC (2008). Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev, CD003917.
36. Yan T, Deng S, Metzger A, Gödtel-Armbrust U, Porter AC, and Wojnowski L (2009). Topoisomerase IIα-dependent and -independent apoptotic effects of dexrazoxane and doxorubicin. Mol Cancer Ther 8, 1075-1085.
37. Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, Jones SE, Wadler S, Desai A, Vogel C, et al. (1997). Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15, 1318-1332.
38. Sehested M, Jensen PB, Sørensen BS, Holm B, Friche E, and Demant EJ (1993). Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochem Pharmacol 46, 389-393.
39. Pommier Y, Leo E, Zhang H, and Marchand C (2010). DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 28, 421-433.
40. Toft KG, Hustvedt SO, Grant D, Martinsen I, Gordon PB, Friisk GA, Korsmo AJ, and Skotland T (1997). Metabolism and pharmacokinetics of MnDPDP in man. Acta Radiol 38, 677-689.
41. Minotti G, Menna P, Salvatorelli E, Cairo G, and Gianni L (2004). Anthra-cyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56, 185-229.
42. Gewirtz DA (1999). A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57, 727-741.
43. Sehested M and Jensen PB (1996). Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle. Biochem Pharmacol 12, 879-886.
44. Classen S, Olland S, and Berger JM (2003). Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187. Proc Natl Acad Sci USA 100, 10629-10634.